Is Ruxolitinib Tablets/Jiekewei a targeted drug?

Ruxolitinib tablets/Ruxolitinib (Ruxolitinib) is a targeted drug that is a selective Janus kinase (JAK) 1 and JAK2 inhibitor, specifically used to regulate abnormally activated signaling pathways. JAK signaling plays a central role in the human blood and immune systems, involved in regulating blood cell production, inflammatory responses, and immune cell activation. When the JAK pathway is abnormally activated, it may lead to the occurrence and progression of diseases such as myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD). Ruxolitinib improves blood system function and alleviates related symptoms by targeting the activity of JAK1/2, reducing the expression of pro-inflammatory cytokines and reducing abnormal blood cell proliferation signals.

In patients with myelofibrosis, ruxolitinib can effectively relieve splenomegaly, fatigue and general discomfort, and improve exercise tolerance and quality of life. In people with polycythemia vera, it regulates hemoglobin and platelet levels, reducing the risk of blood clots and cardiovascular events. In the treatment of graft-versus-host disease, ruxolitinib reduces skin, liver and gastrointestinal symptoms by inhibiting abnormal activation of T cells and the release of inflammatory mediators, and also helps reduce dependence on glucocorticoids.

As a targeted drug, ruxolitinib's advantage lies in its precise intervention in the molecular mechanism of the disease, not just in alleviating symptoms. This targeted therapy not only improves efficacy but also reduces systemic side effects to a certain extent. During long-term use, patients need to conduct hematology monitoring, including platelet count, neutrophil count and hemoglobin level, under the guidance of a physician, in order to adjust the dose in a timely manner and avoid serious adverse events. Clinically, patients should swallow ruxolitinib whole, with food or on an empty stomach. If the dose is missed, it should be adjusted under the guidance of a doctor, and it is not advisable to take it by yourself.

Through scientific medication and standardized follow-up, ruxolitinib has become the core targeted drug for maintenance treatment of patients with myelofibrosis, polycythemia vera andGVHD, providing patients with long-term, stable and accurate treatment options while significantly improving their quality of life.

Reference materials:https://www.jakavi.com/